{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006998","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.191522+00:00","generated_at":"2026-05-16T11:14:41.800394+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cullinan reports $439M cash as of Dec 31, 2025; outlines 2026 clinical milestones for CLN-978, CLN-049, zipalertinib","bullets":["Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.","CLN-978: Phase 1 dose escalation in RA, SLE, SjD ongoing; initial data readouts in Q2/Q3/Q4 2026.","CLN-049: Fast Track for relapsed/refractory AML; dose expansion to determine RP2D in Q4 2026; pivotal trial expected.","Zipalertinib: NDA submission completion expected Q1 2026; REZILIENT3 enrollment complete H1 2026; $130M US milestones + 50% profit share.","Velinotamig: Genrix Bio Phase 1 in China initiated; initial data in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006998","json":"https://secwatch.observer/filing/0001193125-26-006998.json","markdown":"https://secwatch.observer/filing/0001193125-26-006998.md","text":"https://secwatch.observer/filing/0001193125-26-006998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/0001193125-26-006998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:14:41.800394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}